AR and cancer: Using the ENZ-resistant MR49F and androgen-independent LNCaP95 cells models, we show that ICRF187 and ICRF913 potently inhibit AR signaling (Figures 1–3), cancer cell proliferation (Figure 4) and CRPC xenograft growth (Figure 5).